Skip to main content
. Author manuscript; available in PMC: 2015 Jul 21.
Published in final edited form as: Clin Cancer Res. 2015 Feb 4;21(8):1888–1895. doi: 10.1158/1078-0432.CCR-14-1306

Table 4.

PI3K pathway alterations in patients treated at the maximum tolerated dose who remained on-study for > 2 cycles

Patient PI3K
amplification
PI3K
mutation
PTEN status Response
1^ No Not evaluable Absent SD
2 No Yes Absent SD
3 No No Present SD
4 Not evaluable No Absent SD
5 No No Present SD
6 No No Absent SD
7 Not evaluable Not evaluable Absent SD
8 No No Present SD
9* No No Absent SD
^

Last dose: day 8 of cycle 3;

*

last dose: day 7 of cycle 3.